Evidence map›Paper›PMID 32814815›Full record

ArticleScientific reports2020

A novel naphthalimide that selectively targets breast cancer via the arylhydrocarbon receptor pathway.

J Gilbert, G N De Iuliis, A McCluskey, J A Sakoff

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

J GilbertExperimental Therapeutics Group, Department of Medical Oncology, Calvary Mater Newcastle Hospital, Edith Street, Waratah, NSW, 2298, Australia.
G N De IuliisFaculty of Science and Information Technology, Priority Research Centre for Reproductive Science, The University of Newcastle, University Drive, Callaghan, NSW, 2308, Australia.
A McCluskeyChemistry, School of Environmental & Life Sciences, Faculty of Science, The University of Newcastle, University Drive, Callaghan, NSW, 2308, Australia.
J A SakoffExperimental Therapeutics Group, Department of Medical Oncology, Calvary Mater Newcastle Hospital, Edith Street, Waratah, NSW, 2298, Australia. Jennette.sakoff@newcastle.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report that the naphthalimide analogue 2-(2-aminophenyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (NAP-6) is a highly potent and selective breast cancer targeting molecule. These effects are mediated via the aryl hydrocarbon receptor (AHR) pathway and the subsequent induction of CYP1 metabolising monooxygenases in breast cancer cell line models. Indeed the triple negative breast cancer cell line MDA-MB-468 with a GI

Indexed as

Breast NeoplasmsCell Cycle CheckpointsCell Line, TumorCytochrome P-450 CYP1A1Cytochrome P-450 CYP1A2Cytochrome P-450 CYP1B1DNA DamageEnzyme InductionFemaleHT29 CellsHumansMCF-7 CellsMolecular StructureNaphthalimidesReceptors, Aryl HydrocarbonSignal TransductionCYP1A1 protein, humanCYP1A2 protein, humanCYP1B1 protein, humanCytochrome P-450 CYP1A1Cytochrome P-450 CYP1A2Cytochrome P-450 CYP1B1NaphthalimidesReceptors, Aryl Hydrocarbon

Identifiers

PMID32814815
PMCPMC7438328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.